Andere Sprachen Beam Therapeutics Inc.

Aktien

A2PY7P

US07373V1052

BEAM

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.04.2025			% 5 Tage	% 1. Jan.
17,00 ^USD	+2,29 %		+16,20 %	-31,45 %

05.04.	Beam Therapeutics Inc. präsentiert zusätzliche Daten für Beam-302 bei Alpha-1 Antitrypsin-Mangel auf der 7. globalen Forschungskonferenz und dem 10. Patientenkongress der 2025 Alpha-1 Foundation	CI
03.04.	BEAM THERAPEUTICS INC. : RBC Capital Markets gibt neutrale Einschätzung	ZM

Andere Sprachen

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress	05.04.
Beam Therapeutics Inc. Presents Additional Data for Beam-302 in Alpha-1 Antitrypsin Deficiency At 2025 Alpha-1 Foundation 7Th Global Research Conference and 10Th Patient Congress	05.04.
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress	05.04.
Sector Update: Health Care Stocks Steady Premarket Friday	28.03.
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance	27.03.
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration	27.03.
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration	27.03.
Beam Therapeutics Inc. Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency by the United States (U.S.) Food and Drug Administration	27.03.
Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein	10.03.
Beam Therapeutics Prices $500 Million Share, Warrant Offering	10.03.
Beam Therapeutics Announces Pricing Of Underwritten Offering	10.03.
Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels	10.03.
Beam Therapeutics Announces Pricing of Underwritten Offering	10.03.
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation	10.03.
Beam Therapeutics Inc. Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency	10.03.
Beam Therapeutics Swings to Q4 Loss as Revenue Falls	25.02.
Earnings Flash (BEAM) Beam Therapeutics Posts Q4 License and Collaboration Revenue $30.1M, vs. FactSet Est of $17.2M	25.02.
Earnings Flash (BEAM) Beam Therapeutics Posts Q4 Net Loss $1.09 a Share, vs. FactSet Est of $1.23 Loss	25.02.
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	25.02.
Beam Therapeutics Inc. Announces Anticipated Milestones for the Year 2025	25.02.
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts	25.02.
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts	25.02.
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences	24.02.
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference	30.01.
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR	23.01.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bitcoin ETFs sind großartig, aber keine echte Kryptowährung: Beam CEO

Am 30. Januar 2024 um 20:21 Uhr